What is an Aerobika Used For?
The Aerobika is an oscillating positive expiratory pressure (OPEP) device used primarily for airway clearance in patients with chronic obstructive pulmonary disease (COPD), bronchiectasis, and other conditions characterized by chronic mucus hypersecretion.
Primary Indications
The Aerobika device serves as a drug-free, handheld airway clearance therapy that combines two mechanisms:
- Positive expiratory pressure (PEP): Creates back-pressure (5-20 cm H₂O) that stabilizes airways, prevents airway collapse during expiration, and increases gas pressure behind secretions through collateral ventilation 1
- High-frequency oscillations: Generate vibrations within the airway walls that mobilize secretions into the airway lumen and reduce mucus viscosity 2, 3
Evidence-Based Applications
COPD Management
The strongest recent evidence supports Aerobika use in COPD patients with chronic mucus production. In COPD patients, the device demonstrates statistically significant improvements in multiple clinically important outcomes 2, 4, 3:
- Symptom burden: CAT scores improved significantly at 6 weeks (19.02 vs 23.65 baseline, p<0.00001) and further at 12 weeks (16.15, p=0.0052), with 84.8% of patients reaching minimum clinically important difference 2
- Lung function: FEV₁ improved significantly at 12 weeks (p=0.018) and 24 weeks (p=0.001), with sustained improvements in small airway resistance (R5-R20) as early as 12 weeks 4
- Exercise capacity: 6-minute walk distance improved after 24 weeks (p=0.016) 4
- Mucus clearance: Mucus scores decreased significantly from baseline (3.63) to 6 weeks (2.59) and 12 weeks (2.28), both p<0.00001 2
Bronchiectasis
For non-CF bronchiectasis, the evidence is more limited. Guidelines note that while PEP devices have been studied, the quality of evidence remains very low with high risk of bias in available studies 5. A Cochrane review found only one very small crossover study (20 subjects) comparing an Acapella PEP device versus no chest physiotherapy, showing nonsignificant reduction in exacerbations with very low confidence in findings 5.
Cystic Fibrosis
In CF patients, PEP therapy is recommended over conventional chest physiotherapy because it is approximately as effective, inexpensive, safe, and can be self-administered 1. A Cochrane review of 20 studies showed no differences in short-term airway clearance and FEV₁ between PEP and standard physiotherapy, with patients tending to prefer PEP in studies lasting at least 1 month 1.
Clinical Implementation
Prescription Details
- Frequency: Twice daily, 10 minutes per session 2, 4
- Duration: Benefits emerge at 6 weeks with sustained improvements through 12-24 weeks 2, 4
- Patient selection: Target patients with CAT score >10 and mucus score ≥2 2
- Timing: Use before standard inhaled medications to optimize drug deposition patterns 6
Mechanism of Benefit
The device increases specific airway volume by 2.88% after 2 weeks (p=0.048) and shifts internal airflow distribution, which directly correlates with changes in lobar drug deposition (r²=0.30, p<0.001) 6. This means the Aerobika not only clears mucus but also enhances the effectiveness of concomitant inhaled medications.
Important Caveats
Exacerbation prevention: While the device improves symptoms, lung function, and quality of life, current evidence does not show significant reduction in severe exacerbation events in the short term (3-6 months) 4, 3. However, cost-effectiveness analysis suggests it saves $694 in healthcare costs per patient per year with 0.04 more QALYs 7.
Patient acceptance: High satisfaction rates (97.7% would continue using, 88.9% overall satisfaction) support long-term adherence 2.
Safety: No device-related adverse events have been reported in clinical studies 2, 4, 3.
Practical Algorithm
Use Aerobika in patients with:
- COPD with chronic mucus production (CAT >10, mucus score ≥2) - strongest evidence 2, 4
- CF requiring airway clearance - guideline-supported alternative to conventional physiotherapy 1
- Bronchiectasis - may consider as adjunct therapy despite limited evidence 5
Prescribe twice-daily use for minimum 12 weeks to assess benefit, with re-evaluation at 6 and 12 weeks using CAT scores, spirometry, and patient-reported mucus clearance 2, 4.